The AIFA reform and evaluation timelines for new drugs: the impact of the Scientific and Economic Commission
Global and Regional Health Technology Assessment · 19.05.2026 · 13 (1) · 125-132
DOI: 10.33393/grhta.2026.3736 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global and Regional Health Technology Assessment, online erschienen am 19.05.2026. Verfasst von Benedetta Dal Canto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Farmacia, Università di Pisa, Pisa - Italy. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Timely access to new medicines is a key dimension of health system performance. In Italy, pricingand reimbursement decisions are taken by the Italian Medicines Agency (AIFA). In 2024, a reform established theScientific and Economic Commission (CSE), integrating the former Technical-Scientific Committee and Pricing andReimbursement Committee into a single decision-making body. This study evaluates whether the introduction ofthe CSE is associated with changes in the duration of the price and reimbursement process.
Methods
An observational pre-post study was conducted using publicly available AIFA regulatory data. Newchemical entities and orphan medicines under negotiation type 1 reimbursed between January 2022 and January2026 were included. Time intervals were reconstructed from official AIFA committee agendas and comparedbetween pre-reform (CTS/CPR) and post-reform (CSE) periods. Differences were assessed using the Wilcoxonrank-sum test.
Results
The sample included 71 medicines (30 pre-reform; 41 post-reform). The median duration of the evaluationand negotiation phase decreased from 195 to 119 days after the introduction of the CSE (p < 0.004). Overalltime to publication also decreased but not significantly. Administrative timelines remained stable.
Conclusions
The CSE was associated with a significant reduction in evaluation-negotiation timelines, suggestingimproved efficiency in the phase targeted by the reform. However, no significant reduction was observed in overalltimelines, indicating persistent delays in downstream administrative phases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dipartimento di Farmacia, Università di Pisa, Pisa - Italy.
- Laboratorio Management e Salute, Istituto di Management, Scuola Superiore Sant'Anna di Pisa, Pisa - Italy.
- Centro di ricerca interdisciplinare Health Science, Scuola Superiore Sant'Anna di Pisa, Pisa - Italy.
- Direzione Farmaceutico, Dispositivi Medici e Protesica, Area Sanità e Sociale, Regione Veneto, Venezia - Italy.
- Direzione generale dei dispositivi medici e del farmaco, Ministero della Salute, Roma - Italy.
ORCID-Profile: Benedetta Dal Canto, Vera Benedetto, Alma Martelli, Bruna Vinci
Zitieren
APA
Canto, B. D., Benedetto, V., Martelli, A., Scroccaro, G., & Vinci, B. (2026). The AIFA reform and evaluation timelines for new drugs: the impact of the Scientific and Economic Commission. Global and Regional Health Technology Assessment, 13(1), 125-132. https://doi.org/10.33393/grhta.2026.3736
Vancouver
Canto BD, Benedetto V, Martelli A, Scroccaro G, Vinci B. The AIFA reform and evaluation timelines for new drugs: the impact of the Scientific and Economic Commission. Global and Regional Health Technology Assessment. 2026;13(1):125-132. doi:10.33393/grhta.2026.3736
BibTeX
@article{Canto2026,
author = {Canto, Benedetta Dal and Benedetto, Vera and Martelli, Alma and Scroccaro, Giovanna and Vinci, Bruna},
title = {The AIFA reform and evaluation timelines for new drugs: the impact of the Scientific and Economic Commission},
journal = {Global and Regional Health Technology Assessment},
year = {2026},
volume = {13},
number = {1},
pages = {125--132},
doi = {10.33393/grhta.2026.3736}
}
EUVIMED